A5072596232- Streptococcal Infections and Treatments
- Antimicrobial Resistance in Staphylococcus
- Neonatal and Maternal Infections
- SARS-CoV-2 and COVID-19 Research
- Infective Endocarditis Diagnosis and Management
- Otolaryngology and Infectious Diseases
- vaccines and immunoinformatics approaches
- Vaccine Coverage and Hesitancy
- COVID-19 Clinical Research Studies
- Inflammasome and immune disorders
- Polyomavirus and related diseases
- Biochemical and Structural Characterization
- Immune Response and Inflammation
- Pneumonia and Respiratory Infections
- Respiratory viral infections research
- Monoclonal and Polyclonal Antibodies Research
- Viral gastroenteritis research and epidemiology
- Immunotherapy and Immune Responses
- Plant Virus Research Studies
- Viral Infectious Diseases and Gene Expression in Insects
- Bacterial Infections and Vaccines
- Influenza Virus Research Studies
- Animal Virus Infections Studies
- Bartonella species infections research
- Viral Infections and Immunology Research
The University of Queensland
2011-2024
Centro Medico Nacional Siglo XXI
2019-2024
Mexican Social Security Institute
2019-2024
Hospital de Especialidades
2019-2024
Consejo Nacional de Humanidades, Ciencias y Tecnologías
2019-2024
Griffith University
2016
Center for Research and Advanced Studies of the National Polytechnic Institute
2012
Instituto Politécnico Nacional
2012
The rise of bacterial antibiotic resistance coupled with a reduction in new development has placed significant burdens on global health care. Resistant pathogens such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus are leading causes community- hospital-acquired infection present clinical challenge. These have acquired to broad classes antimicrobials. Furthermore, Streptococcus pyogenes , disease agent among Indigenous Australians, now several classes....
Group A Streptococcus (GAS) infections account for an estimated 500,000 deaths every year. This bacterial pathogen is responsible a variety of mild and life-threatening the triggering chronic autoimmune sequelae. Pharyngitis caused by group (GAS), but not asymptomatic GAS carriage, prerequisite acute rheumatic fever (ARF). Repeated bouts ARF may trigger heart disease (RHD), major cause failure stroke accounting 275,000 annually. vaccine that prevents pharyngitis would markedly reduce...
Abstract The re-emergence of scarlet fever poses a new global public health threat. capacity North-East Asian serotype M12 ( emm 12) Streptococcus pyogenes (group A , GAS) to cause has been linked epidemiologically the presence novel prophages, including prophage ΦHKU.vir encoding secreted superantigens SSA and SpeC DNase Spd1. Here, we report molecular characterization ΦHKU.vir-encoded exotoxins. We demonstrate that streptolysin O (SLO)-induced glutathione efflux from host cellular stores...
BackgroundStreptococcus pyogenes is a leading cause of infection-related morbidity and mortality. A reinvigorated vaccine development effort calls for new clinically relevant human S experimental infection models to support proof concept evaluation candidate vaccines. We describe the initial Controlled Human Infection Vaccination Against (CHIVAS-M75) study, in which we aimed identify dose emm75 that causes acute pharyngitis at least 60% volunteers when applied pharynx by swab.MethodsThis...
Group A Streptococcus (GAS) is an important human pathogen responsible for both superficial infections and invasive diseases. Autoimmune sequelae may occur upon repeated infection. For this reason, development of a vaccine against GAS represents major challenge, since certain components trigger autoimmunity. We formulated three combination vaccines containing the following: (i) streptolysin O (SLO), interleukin 8 (IL-8) protease (Streptococcus pyogenes cell envelope proteinase [SpyCEP]),...
Recent global advocacy efforts have highlighted the importance of development a vaccine against group A Streptococcus (GAS). Combo5 is non-M protein-based that provides protection GAS skin infection in mice and reduces severity pharyngitis nonhuman primates. However, with addition aluminum hydroxide (alum) as an adjuvant failed to protect invasive mice. Here, we show formulation adjuvants containing saponin QS21 significantly improves protective efficacy, even though all 7 tested generated...
The hydroxyquinoline analog PBT2 breaks resistance to polymyxin class antibiotics in polymyxin-resistant Gram-negative bacteria.
GAS ( Streptococcus pyogenes ) is a leading global cause of infection-related morbidity and mortality. A modern CHIM pharyngitis could help to accelerate vaccine development drive pathogenesis research. Challenge strain selection critical the safety success any especially so for an organism such as GAS, with its wide diversity potential severe life-threatening acute infections (e.g., toxic shock syndrome necrotizing fasciitis) postinfectious complications rheumatic fever, heart disease,...
Abstract Pili of Group A Streptococcus (GAS) are surface-exposed structures involved in adhesion and colonisation the host during infection. The major protein component GAS pilus is T-antigen, which multimerises to form shaft. There currently no licenced vaccines against infections T-antigen represents an attractive target for vaccination. We have generated a multivalent vaccine called TeeVax1, recombinant that consists fusion six domains. Vaccination with TeeVax1 produces opsonophagocytic...
The immunobiology underlying the slow acquisition of skin immunity to group A streptococci (GAS), is not understood, but attributed specific virulence factors impeding innate and significant antigenic diversity type-specific M-protein, hindering acquired immunity. We used a number epidemiologically distinct GAS strains model development show that infection leads antibody responses serotype-specific determinants on M-protein profound protective immunity; however, memory B cells do develop...
Modularization of a peptide antigen for presentation on microbially synthesized murine polyomavirus (MuPyV) virus-like particle (VLP) offers new alternative rapid and low-cost vaccine delivery at global scale. In this approach, heterologous modules containing antigenic elements are fused to displayed the VLP carrier, allowing enhancement immunogenicity via ordered densely repeated modules. This study addresses two key engineering questions pertaining platform, exploring effects (i)...
Identifying the immunogenic moieties and their precise structure of carbohydrates plays an important role for developing effective carbohydrate-based subunit vaccines. This study assessed structure-immunogenicity relationship carbohydrate a single repeating unit group A (GAC) present on cell wall Streptococcus (GAS) using rationally designed self-adjuvanted lipid-core peptide, instead carrier protein. Immunological evaluation fully synthetic glyco-lipopeptides (particle size: 300-500 nm)...
Streptococcus pyogenes (Group A Streptococcus; GAS) commonly causes pharyngitis in children and adults, with severe invasive disease immune sequelae being an infrequent consequence. The ability of GAS to invade the host establish infection likely involves subversion defenses. However, signaling pathways innate responses epithelial cells are not well understood. In this study, we utilized RNAseq characterize inflammatory primary human tonsil (TEpi) laboratory-adapted M6 strain JRS4 M1T1...
Streptococcus pyogenes (group A streptococcus, GAS) causes a wide range of clinical manifestations ranging from mild self-limiting pyoderma to invasive diseases such as sepsis. Also concern are the post-infectious immune-mediated including rheumatic heart disease. The development vaccine against GAS would have large health impact on populations at risk these diseases. However, there is lack suitable models for safety evaluation vaccines with respect complications. We utilized Lewis Rat model...
Abstract Antigenic diversity of the M protein is a major constraint to development immunity group A streptococcus (GAS). We demonstrate that conserved cryptic epitope unrecognized by host immune system following infection can protect mice vaccination, and strengthened broadened successive infections. The observation boost broaden, but cannot prime epitope, may be exploited for vaccines other pathogens.